Novel treatment options for juvenile idiopathic arthritis.

about

Novel treatment options for juvenile idiopathic arthritis.

Item

http://www.wikidata.org/entity/Q38570721

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Novel treatment options for juvenile idiopathic arthritis.

@en

type

Item

label

Novel treatment options for juvenile idiopathic arthritis.

@en

prefLabel

Novel treatment options for juvenile idiopathic arthritis.

@en

P1476

Novel treatment options for juvenile idiopathic arthritis.

@en

P2093

Katherine A Steigerwald

http://www.w3.org/2001/XMLSchema#string

Norman T Ilowite

http://www.w3.org/2001/XMLSchema#string

P2860

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Certolizumab pegol for the treatment of Crohn's disease

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

P304

559-573

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2015.1061428

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26294075

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

Novel treatment options for juvenile idiopathic arthritis.

about

Novel treatment options for juvenile idiopathic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921